替吉奥联合紫杉醇或奥沙利铂治疗进展期胃癌的临床观察

doi:10.3971/j.issn.1000-8578.2014.07.027

替吉奥联合紫杉醇或奥沙利铂治疗进展期胃癌的临床观察

Clinical Observation of S-1 Combined with Oxaliplatin or Paclitaxel on Advanced Gastric Cancer

摘要

摘要: 目的观察替吉奥（S-1）联合紫杉醇或奥沙利铂一线治疗进展期胃癌的临床疗效和不良反应。方法 91例进展期胃癌患者分为替吉奥联合奥沙利铂(SOX组)和紫杉醇(PS组)方案化疗，其中SOX组44 例，PS组47例。所有患者S-1均是80 mg/m2，分2次餐后口服，d1~d14；SOX组：奥沙利铂 130 mg/m2，d1，静脉滴注；PS组：紫杉醇 80 mg/m2，d1、8，静脉滴注。均21天为1周期。结果 SOX组和PS组的有效率分别为36.4%和40.4%(P=0.691)，两组的中位无疾病进展时间(5.0月 vs. 5.4 月，P=0.45)和中位生存时间(13.5月 vs. 16.4月，P=0.76)无显著差异。SOX组和PS组的不良反应主要是中性粒细胞减少、胃肠道反应、乏力；SOX组和PS组的恶心、呕吐发生率分别为79.5％和51.1％(P＜0.05)。结论替吉奥联合紫杉醇或奥沙利铂治疗进展期胃癌有效率和生存期相当，均有较好的疗效，不良反应可以耐受。

Abstract: Objective To observe the efficacy and adverse reaction of S-1 combined with oxaliplatin or paclitaxel in the treatment of advanced gastric cancer. Methods Ninety-one advanced gastric carcinoma patients were divided into two groups: SOX group(44 cases, S-1 plus oxaliplatin) and PS group (47 cases, S-1 plus paclitaxel). All cases took oral S-1, 80 mg/m2/day, d1~14; Moreover, SOX group took oxaliplatin, 130 mg /m2 on d1; PS group took paclitaxel, 80mg /m2 on d1, d8. 21 days was a cycle. Results RR in group SOX and PS were 36.4% and 40.4% (P=0.691), respectively. PFS was 5.0 months in SOX group and 5.4 months in PS group (P=0.45). OS was 13.5 months in SOX group and 16.4 months in PS group (P=0.76). Main adverse effects in two groups were neutropenia, gastrointestinal reaction and fatigue. The frequency of nausea and vomiting was 79.5% in SOX group and 51.1% in PS group(P＜0.05). Conclusion RR and OS of S-1 combined with SOX or PS were similar, with good curative effect and tolerable adverse reactions.

HTML全文

参考文献(15)

施引文献

资源附件(0)